Vyleesi VA Coverage Pathway: How to Get Bremelanotide Covered or Cheaper in 2026

What Is Vyleesi and Who Is It For?

Bremelanotide, sold as Vyleesi, is a subcutaneous auto-injector taken 45 minutes before anticipated sexual activity to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the second FDA-approved drug for HSDD, after flibanserin (Addyi). Unlike Addyi, you take it on demand rather than daily.

HSDD is the most common female sexual dysfunction, affecting an estimated 8 to 10 percent of women across reproductive years. The FDA granted bremelanotide approval in June 2019 based on two key Phase 3 trials, RECONNECT-A and RECONNECT-B, which showed statistically significant improvements in desire and reductions in distress compared with placebo in premenopausal women aged 18 to 55.

Who the FDA Indication Covers

The approval covers premenopausal women with acquired, generalized HSDD. "Acquired" means the condition developed after a period of normal sexual desire. "Generalized" means it occurs regardless of partner, situation, or type of stimulation. If your low desire has always been there (lifelong) or is situational, bremelanotide is not the indicated treatment.

Life-Stage Framing

• Reproductive years (18 to 45): This is the primary target population from the RECONNECT trials.
• Perimenopause: Hormonal fluctuation during perimenopause can cause HSDD, but the FDA label does not cover perimenopausal women who still have cycles. Data specifically in this group are limited. Your provider may consider it off-label.
• Postmenopause: Bremelanotide is not FDA-indicated for postmenopausal women. The RECONNECT trials excluded postmenopausal participants. Any use here is extrapolated, not directly studied. Be candid with your provider about this evidence gap.
• PCOS: Low desire is reported more frequently in women with PCOS, though bremelanotide has not been studied specifically in that population.

How Much Does Vyleesi Cost Without Insurance?

The average cash price for one monthly supply of Vyleesi (eight single-dose 1.75 mg auto-injectors) is approximately $1,200 at major retail pharmacies. Palatin Technologies lists the wholesale acquisition cost at a level that puts retail near that figure after standard pharmacy markup.

That number is not accessible for most women. One eight-injector pack treats you for, at most, eight sexual encounters per month. Many women use two to four injectors per month in practice, but the box still costs the same.

Why the Price Is So High

Bremelanotide is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. Peptide synthesis at pharmaceutical scale is expensive, and Vyleesi remains brand-only with no generic competitor as of 2026. Palatin holds patent protection through the mid-2030s.

VA Coverage for Vyleesi: The Step-by-Step Pathway

The VA does not place bremelanotide on its national formulary as of 2026. That does not mean you cannot get it through the VA. It means you need to go through the non-formulary process, which requires more paperwork but has succeeded for women veterans with documented HSDD.

Step 1: Establish Care with a VA Women's Health Provider

VA medical centers are required to have a Women Veterans Program Manager and, at most sites, a designated women's health primary care provider. The VA Office of Women's Health can help you locate your nearest clinic. Book an appointment specifically for sexual health or hormonal concerns rather than a general visit so your provider can allocate adequate time.

Step 2: Get a Formal HSDD Diagnosis

Your provider needs to document HSDD in your chart using DSM-5 criteria. That means a persistent or recurrent deficiency in sexual desire causing marked distress, not better explained by another mental health condition, relationship problem, medication effect, or medical condition. A validated screening tool, such as the Female Sexual Function Index (FSFI), is commonly used to support documentation.

Military sexual trauma, PTSD, and antidepressant use are highly prevalent among women veterans and all can suppress desire independently. Your VA provider should screen for and treat those first. Bremelanotide will not work well if an SSRI is the primary driver of your low desire.

Step 3: Try and Fail At Least One Formulary Alternative

VA formulary reviewers typically expect evidence of an adequate trial of a formulary option before approving a non-formulary request. Options your provider may document include:

• Counseling or sex therapy referral
• Switching or reducing dose of a libido-suppressing medication (e.g., SSRI)
• Testosterone therapy (off-label; not FDA-approved for HSDD but sometimes used)
• Flibanserin (Addyi), which is also non-formulary at most VA sites but may be easier to justify as the first-line FDA-approved HSDD medication

Step 4: Submit a Non-Formulary Drug Request

Your prescribing provider submits an NFDR through the VA's Computerized Patient Record System (CPRS). The request should include:

1. Diagnosis with DSM-5 criteria documented
2. Failed or contraindicated alternatives
3. Clinical rationale for bremelanotide specifically
4. Proposed dose (1.75 mg subcutaneous, as needed, no more than once per 24 hours, maximum eight doses per month per labeling)

The pharmacy benefits management (PBM) committee at your VA facility reviews the request. Decisions typically take 2 to 4 weeks. You can ask your provider or patient advocate for status updates.

Step 5: Appeal If Denied

If the NFDR is denied, you have the right to appeal through the VA's clinical appeals process. Engage your VA Patient Advocate (every medical center has one). A letter from a VA OB-GYN or gynecologist supporting the request strengthens an appeal significantly.

The five-step VA access framework above (establish care, document diagnosis, trial formulary alternatives, submit NFDR, appeal if needed) is a WomanRx editorial synthesis based on VA PBM policy and women veteran health program guidance. No single source maps it in this sequential form for HSDD specifically.

Commercial Insurance Coverage for Vyleesi

Most major commercial insurers classify bremelanotide as a specialty drug and place it on Tier 4 or Tier 5, with cost-sharing that can still run $200 to $600 per fill even with insurance. Coverage decisions are plan-specific. Here is how to build your case.

Check Your Formulary First

Log into your insurer's member portal and search for "bremelanotide" and "Vyleesi." Plans that cover it often require prior authorization. Plans that do not cover it at all may still offer an exception pathway.

Prior Authorization Requirements

Most insurers that cover Vyleesi require documentation of:

• Premenopausal status
• DSM-5 HSDD diagnosis from a licensed provider
• Exclusion of secondary causes (hormonal, psychiatric, medication-related)
• Failure of or contraindication to non-pharmacologic management (counseling)

Some plans additionally require a urine pregnancy test result or documentation of contraceptive use, which aligns with the drug's pregnancy risk (see the pregnancy section below).

Step Therapy and Flibanserin

A minority of plans require you to try flibanserin (Addyi) before approving bremelanotide. Flibanserin has a daily dosing schedule, a moderate alcohol restriction, and a Risk Evaluation and Mitigation Strategy (REMS) program, which some women find burdensome. If you tried Addyi and it did not work or caused side effects, document that clearly. Intolerance of one FDA-approved HSDD agent is usually sufficient to justify a step therapy exception.

Medicare and Medicaid

Medicare Part D generally does not cover drugs for sexual dysfunction under the statutory exclusion for "agents when used for cosmetic purposes or hair growth" interpreted broadly. HSDD is not cosmetic, and some plans have covered Vyleesi under Part D exceptions, but this is uncommon. Medicaid coverage varies by state; most states do not cover it.

The Palatin Manufacturer Savings Card

Palatin Technologies offers a patient savings program for commercially insured patients. Eligible women may pay as little as $0 per fill through the savings card. As of 2026, the program is available at participating pharmacies for patients with commercial insurance (not VA, Medicare, or Medicaid).

Key terms to verify directly with Palatin:

• Income limits (programs change; verify before relying on this)
• Maximum benefit per year
• Which pharmacies participate
• Whether you need to enroll before your first fill

Savings programs expire or restructure. Call the Palatin patient support line listed on the Vyleesi website before your prescription is written so you know what to expect at the pharmacy counter.

Compounded Bremelanotide: Lower Cost, More Complexity

Compounded bremelanotide is available from FDA-registered 503A and 503B outsourcing pharmacies at an average cost of approximately $140 per month. That is roughly an 88 percent reduction from the cash price of the brand-name product.

What Compounding Means Here

Compounded bremelanotide is not FDA-approved. The active pharmaceutical ingredient (API) is synthesized outside the Palatin manufacturing process and prepared by a compounding pharmacy. Quality standards vary. The FDA has not inspected or verified the purity, potency, or sterility of every compounding pharmacy's product.

The FDA's 503B outsourcing facility framework provides higher quality assurance than a traditional 503A compounding pharmacy. For an injectable peptide like bremelanotide, sterility is not optional. Choose a pharmacy that is FDA-registered as a 503B facility or that has current USP 797 (sterile compounding) accreditation.

Dose Equivalence Is Not Guaranteed

Brand Vyleesi delivers exactly 1.75 mg per auto-injector. Compounded versions may be prepared at different concentrations (e.g., 2 mg/0.5 mL in a vial with a separate syringe). If you switch from brand to compounded, confirm the dose with your provider and the pharmacy.

Insurance Will Not Reimburse Compounded Bremelanotide

Compounded drugs are not reimbursable under most commercial plans or VA benefits. You pay cash. Factor that into your decision, especially if you are close to meeting a deductible with brand Vyleesi.

Pregnancy, Lactation, and Contraception: Required Reading

Bremelanotide is contraindicated in pregnancy. Stop using it before any conception attempt.

Pregnancy Safety Data

The FDA labeling for Vyleesi states that animal reproduction studies showed embryofetal toxicity at doses approximately 8 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. If you become pregnant during use, stop bremelanotide immediately and contact your provider.

Bremelanotide causes transient increases in blood pressure and decreases in heart rate with each dose. These hemodynamic effects are not trivial in early pregnancy, when cardiovascular adaptation is already under way.

There is no FDA pregnancy category system for drugs approved after 2015; the current labeling uses the narrative format required by the Pregnancy and Lactation Labeling Rule (PLLR).

Lactation

It is unknown whether bremelanotide or its metabolites are excreted in human breast milk. The FDA label advises that because of the potential for serious adverse reactions in a breastfed infant, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need and any potential adverse effects. In plain terms: the data do not exist to call it safe in lactation.

If you are postpartum and breastfeeding, discuss timing with your provider. Postpartum HSDD is extremely common and often driven by hypoestrogenism plus elevated prolactin. Treating those hormonal drivers first is more evidence-based than introducing an unstudied drug during lactation.

Contraception Requirement

Bremelanotide is not a contraceptive. Given its embryofetal toxicity in animal studies, you should use reliable contraception while on it if you are not trying to conceive. If you are trying to conceive, stop bremelanotide first.

Sex-Specific Pharmacology: How Bremelanotide Works in Your Body

Bremelanotide is a melanocortin receptor agonist. It binds primarily to MC4R receptors in the central nervous system, modulating dopaminergic and noradrenergic circuits that regulate sexual desire. It does not act peripherally or on genital blood flow in the way sildenafil does in men.

Hormonal Status Changes the Context

The RECONNECT trials enrolled premenopausal women, so the pharmacodynamic data we have comes from women with endogenous estrogen and progesterone cycling. Whether bremelanotide works the same way in the hypoestrogenic environment of menopause has not been tested. One small open-label study in postmenopausal women showed some effect on desire scores, but this predates the current formulation and cannot be directly compared to RECONNECT.

The menstrual cycle phase does not appear to change bremelanotide's pharmacokinetics significantly based on available data, but cycle phase does change baseline desire. Women often find desire naturally higher in the follicular phase (days 7 to 14). Whether you would need the drug less frequently at that time has not been formally studied.

Side Effects With Female-Relevant Notes

The most common adverse effects from the RECONNECT trials were:

• Nausea: occurred in approximately 40 percent of women in the bremelanotide arm versus 15 percent placebo
• Flushing: approximately 20 percent
• Injection site reactions: approximately 17 percent
• Transient blood pressure increase: mean peak systolic increase of approximately 6 mmHg, lasting 12 hours
• Hyperpigmentation: focal facial hyperpigmentation reported with repeated doses, particularly in women with darker skin tones. The FDA label recommends no more than one dose per 24 hours and cautions against use in women with a history of hyperpigmentation disorders.

Women with a history of cardiovascular disease, uncontrolled hypertension, or a high baseline cardiovascular risk should not use bremelanotide. The 12-hour blood pressure elevation is clinically meaningful in that group.

Who This Is Right For and Who Should Look Elsewhere

Right for You If:

• You are premenopausal with documented, distressing HSDD (acquired and generalized)
• Secondary causes (medication side effects, hormonal deficiency, relationship conflict, depression) have been assessed and addressed
• You do not have cardiovascular disease or uncontrolled hypertension
• You want an on-demand option rather than a daily pill
• You are not pregnant, not trying to conceive, and not breastfeeding

Not the Right Fit If:

• Your low desire is lifelong or situational
• You are postmenopausal (no trial data; off-label with unclear benefit)
• You have a history of facial hyperpigmentation or melasma
• You are pregnant or breastfeeding
• You have cardiovascular disease or blood pressure that is not well controlled
• Your HSDD is primarily driven by an SSRI and you have not yet tried dose reduction or switching to an SSRI with less sexual side-effect burden (e.g., bupropion augmentation)
• You are a Medicare or Medicaid beneficiary without access to the manufacturer savings program and cannot afford $1,200/month cash

How to Have the Conversation With Your Provider

Many women do not bring up sexual desire concerns because they expect to be dismissed. A 2019 survey published in Obstetrics and Gynecology found that fewer than half of women with sexual dysfunction had discussed it with a clinician in the past year, citing embarrassment and expectation of being ignored as the top barriers.

You deserve a direct conversation. Here is language you can use:

"I have noticed a significant drop in my desire for sex that is causing me real distress in my relationship and my sense of self. I want to discuss whether bremelanotide is appropriate for me and, if so, how to make it affordable."

That framing meets the DSM-5 criteria language (deficiency causing marked distress) and signals you have done some research. A provider who dismisses that statement without a proper assessment is not providing adequate women's health care.

Programs That Change: How to Stay Current

Access programs for specialty drugs shift frequently. The Palatin savings card may restructure. VA formulary decisions get reviewed annually. Compounding pharmacy regulations can tighten on short notice.

Before filling any prescription:

1. Verify the manufacturer savings program at vyleesi.com or by calling Palatin's patient support line
2. Call your VA pharmacy or PBM to confirm current non-formulary status and any new formulary additions
3. Confirm your compounding pharmacy's 503B registration at FDA's outsourcing facility list
4. Check your insurance formulary at the start of every plan year (January 1 for most plans)